BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 16200709)

  • 1. [T-cell immunity against autologous leukemic cell mediated by in vitro bone marrow-derived dendritic cell from patients with acute myeloid leukemia in complete remission].
    He X; You S; Bian S
    Zhonghua Xue Ye Xue Za Zhi; 2001 Dec; 22(12):629-32. PubMed ID: 16200709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Induction of efficient T-cell immunity against autologous leukemia cells by dendritic cells pulsed with the leukemia cell total RNA].
    Ge W; You SG; Wang YF; Li CH; Liu XF; He XP; Ma S; Qiu L
    Zhonghua Xue Ye Xue Za Zhi; 2005 Aug; 26(8):461-4. PubMed ID: 16383235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Investigation on specific killing acute leukemia cell reaction of the cytotoxic T lymphocyte induced by dendritic cell pulsed with frozen-thawed antigen].
    He B; Qiu G; Xie X
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2004 Dec; 21(6):974-8. PubMed ID: 15646345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of leukemia-specific cytotoxic response by cross-presentation of late-apoptotic leukemic blasts by autologous dendritic cells of nonleukemic origin.
    Spisek R; Chevallier P; Morineau N; Milpied N; Avet-Loiseau H; Harousseau JL; Meflah K; Gregoire M
    Cancer Res; 2002 May; 62(10):2861-8. PubMed ID: 12019165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of leukemic-cell-specific cytotoxic T lymphocytes by autologous monocyte-derived dendritic cells presenting leukemic cell antigens.
    Lee JJ; Park MS; Park JS; Kang HK; Kim SK; Nguyen Pham TN; Zhu XW; Cho D; Nam JH; Kim YJ; Rhee JH; Chung IJ; Kim HJ
    J Clin Apher; 2006 Oct; 21(3):188-94. PubMed ID: 16570260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
    Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
    Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
    J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Induction of T cell responses against autologous ovarian cancer by anti-idiotype minibody-pulsed dendritic cells].
    Yang WL; Cui H; Feng J; Chang XH; Fu TY; Ye X; Zhang H; Li XP; Wen HW; Feng LM; Tong CR
    Ai Zheng; 2004 Dec; 23(12):1639-45. PubMed ID: 15601552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions.
    Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schweiger C; Nuessler V; Schmid C; Kolb HJ; Schmetzer HM
    Scand J Immunol; 2005 Jul; 62(1):86-98. PubMed ID: 16091128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dendritic cells (DC) induced from acute myeloid leukemia (AML) cells with cytokine cocktails].
    Yan KH; You SG; Bian SG; Ma GJ; Ge W; Ma S; Liu SH; Zhao CH
    Zhonghua Xue Ye Xue Za Zhi; 2003 Jul; 24(7):365-8. PubMed ID: 12941192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of autologous leukemia-specific T cells in acute myeloid leukemia: monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells.
    Draube A; Beyer M; Wolf J
    Eur J Haematol; 2008 Oct; 81(4):281-8. PubMed ID: 18573171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The T cells activated by dendritic cells derived from AML cells: a study of their cytotoxic effect on autologous AML cells].
    Xiang B; Li SF; Zhou J; Mao YQ; Yang YM; Liu T
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):784-7. PubMed ID: 15573754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The comparison of inducing specific CTL by two methods of leukemia cell antigen loading of DCs and fusion of DCs with leukemia cells].
    Sheng LX; Qiu GQ; Xie XB; Gu WY; Wang ZL; Wu HQ
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Mar; 21(2):205-9. PubMed ID: 15766407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of the concentration of autologous serum for generation of leukemic dendritic cells from acute myeloid leukemic cells for clinical immunotherapy.
    Choi BH; Kang HK; Park JS; Kim SK; Pham TN; Zhu XW; Cho D; Nam JH; Chung IJ; Kim YJ; Rhee JH; Kim HJ; Lee JJ
    J Clin Apher; 2006 Dec; 21(4):233-40. PubMed ID: 17120232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In vitro anti-tumor effect of CTL induced by HSP70-Id complex-modified dendritic cells].
    Wang ZH; Ye Q; Hu ZQ; Ye ZQ; Yu X; Shen GX
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):481-5. PubMed ID: 17147108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential.
    Liepert A; Grabrucker C; Kremser A; Dreyssig J; Ansprenger C; Freudenreich M; Kroell T; Reibke R; Tischer J; Schweiger C; Schmid C; Kolb HJ; Schmetzer H
    Cell Immunol; 2010; 265(1):23-30. PubMed ID: 20663492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [An in vitro study of specific antitumor immunity induced by dendritic cells pulsed with tumor cell lysates from patients with hepatocellular carcinoma].
    Gao J; Chen M; Peng ML; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2005 Mar; 13(3):198-201. PubMed ID: 15760555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells.
    Curti A; Pandolfi S; Aluigi M; Isidori A; Alessandrini I; Chiodoni C; Testoni N; Colombo MP; Baccarani M; Lemoli RM
    Exp Hematol; 2005 Dec; 33(12):1521-30. PubMed ID: 16338495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukaemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with myelodysplasia: a methodological approach under serum-free culture conditions.
    Kufner S; Zitzelsberger H; Kroell T; Pelka-Fleischer R; Salem A; de Valle F; Schmid C; Schweiger C; Kolb HJ; Schmetzer HM
    Scand J Immunol; 2005 Jul; 62(1):75-85. PubMed ID: 16091127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods.
    Kremser A; Dressig J; Grabrucker C; Liepert A; Kroell T; Scholl N; Schmid C; Tischer J; Kufner S; Salih H; Kolb HJ; Schmetzer H
    J Immunother; 2010; 33(2):185-99. PubMed ID: 20139775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.